# MUSK Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The MUSK gene encodes a receptor tyrosine kinase critical for neuromuscular junction (NMJ) formation and maintenance, orchestrating acetylcholine receptor (AChR) clustering in response to neural agrin.
- Pathogenic biallelic germline mutations in MUSK lead to Congenital Myasthenic Syndrome 9 (CMS9) and Fetal Akinesia Deformation Sequence (FADS), characterized by fatigable muscle weakness and, in severe cases, prenatal akinesia.
- Autoimmune targeting of MUSK by IgG4 antibodies defines MuSK-antibody-positive myasthenia gravis (MuSK-MG), presenting with prominent bulbar and respiratory weakness, often accompanied by muscle atrophy.
- Therapeutic strategies for MUSK-related disorders include acetylcholinesterase inhibitors and potassium channel blockers for CMS, while MuSK-MG is managed with immunosuppressants and plasmapheresis.
- Investigational therapies include MUSK agonist antibodies that bypass agrin/LRP4 signaling to restore NMJ function in CMS, and AAV-mediated gene replacement for genetic forms of the disorder.

---

## Executive Summary & Key Metadata

The **MUSK** gene (Muscle-Specific Kinase) encodes a receptor tyrosine kinase (RTK) that is indispensable for the formation, maintenance, and function of the neuromuscular junction (NMJ). MUSK operates as the central postsynaptic organizer, orchestrating the clustering of acetylcholine receptors (AChRs) and the differentiation of the postsynaptic membrane in response to neural agrin. Its dysfunction—whether through biallelic pathogenic germline mutations or autoimmune targeting by antibodies—results in severe neuromuscular disorders, including congenital myasthenic syndromes (CMS) and myasthenia gravis (MuSK-MG). The protein's modular architecture, comprising three extracellular immunoglobulin-like domains, a cysteine-rich domain, a single-pass transmembrane helix, and a cytoplasmic tyrosine kinase domain, enables its dual roles in ligand binding and intracellular signaling.

| **Attribute** | **Value** |
|---|---|
| **HGNC Symbol** | MUSK |
| **UniProt Accession** | O15146 |
| **Representative PDB ID** | 2NRL (kinase domain), 3HKL (Ig1-2 domains) |
| **Chromosomal Locus** | 9q31.3-q32 (GRCh38: chr9:110,668,791-110,807,437) |
| **Primary Molecular Function** | Receptor tyrosine kinase; agrin/LRP4 signaling; AChR clustering; NMJ formation |
| **Disease & Pathology Associations** | Congenital Myasthenic Syndrome 9 (CMS9; OMIM 616325); Fetal Akinesia Deformation Sequence (FADS); MuSK antibody-positive Myasthenia Gravis (MuSK-MG) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The human MUSK gene is located on the long arm of chromosome 9, specifically at cytogenetic band **9q31.3-q32**. The gene spans approximately 138.6 kilobases (kb) of genomic DNA, oriented on the minus strand of the reference genome (GRCh38/hg38). The genomic coordinates are chr9:110,668,791–110,807,437 (Ensembl ENSG00000035720). The gene comprises **20 exons** and **19 introns**, with the translation initiation codon located in exon 2 and the stop codon in exon 20. The mature mRNA transcript is approximately 4.5 kb in length, with a 5' untranslated region (UTR) of ~200 nucleotides and a 3' UTR of ~1.5 kb that contains multiple AU-rich elements (AREs) implicated in mRNA stability regulation.

### 1.2 Promoter Architecture and Regulatory Elements

The MUSK promoter lacks a canonical TATA box but contains a high GC content (approximately 70%) and multiple Sp1 binding sites, characteristic of housekeeping-like promoters that nevertheless exhibit tissue-specific regulation. The core promoter region spans ~500 bp upstream of the transcription start site (TSS). A critical regulatory feature is the **N-box element** (consensus: CCGGAA), located approximately 80 bp upstream of the TSS. This element is bound by the ETS-domain transcription factor **GABPα/β** (GA-binding protein), which mediates nerve-dependent and activity-dependent transcriptional activation of MUSK [55]. The N-box is essential for the synapse-specific expression of MUSK, as its mutation abolishes agrin-induced transcriptional upregulation.

A second regulatory region, the **E-box**, is located within the first intron. This element is recognized by myogenic basic helix-loop-helix (bHLH) transcription factors, notably **MyoD** and **myogenin**. Tang et al. demonstrated that a muscle-specific enhancer within the human MuSK promoter requires myogenin binding for activity-dependent gene regulation [55]. This enhancer is responsive to electrical activity and agrin signaling, establishing a positive feedback loop where MUSK signaling drives its own transcription.

### 1.3 Enhancer Elements and Chromatin Architecture

Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from skeletal muscle myotubes reveals that the MUSK locus is marked by H3K27ac (active enhancer) and H3K4me1 (poised enhancer) histone modifications at several intergenic regions, particularly at ~50 kb upstream of the TSS. These regions are predicted to contain binding sites for **MEF2** (myocyte enhancer factor-2) and **SRF** (serum response factor), which coordinate muscle-specific gene expression. Additionally, CTCF (CCCTC-binding factor) insulator sites flank the MUSK locus, defining a topologically associating domain (TAD) that isolates MUSK regulatory elements from neighboring genes.

### 1.4 Alternative Splicing and Isoforms

Alternative splicing of MUSK generates multiple transcript variants, although the functional significance of most remains incompletely characterized. The major isoforms include:

- **MUSK-001 (Canonical)**: Encodes the full-length 869-amino acid protein (UniProt O15146-1). This isoform includes all 20 exons and is the predominant form in skeletal muscle.
- **MUSK-002**: Skips exon 10, which encodes part of the juxtamembrane region. This isoform lacks a portion of the cytoplasmic domain and exhibits reduced kinase activity in vitro.
- **MUSK-003**: Uses an alternative 3' splice acceptor site in exon 15, resulting in a truncated kinase domain. This isoform is predicted to be catalytically inactive and may function as a dominant-negative regulator.
- **MUSK-004**: Retains intron 16, introducing a premature stop codon. This transcript is likely targeted for nonsense-mediated decay (NMD).

Tissue-specific splicing is regulated by the RNA-binding proteins **PTBP1** (polypyrimidine tract-binding protein 1) and **nPTB** (neural PTB). In non-neural tissues, PTBP1 represses the inclusion of exon 10, whereas in muscle and nerve, nPTB promotes its inclusion. This splicing switch is critical for proper MUSK function at the NMJ.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The MUSK protein is a type I single-pass transmembrane receptor tyrosine kinase of 869 amino acids (molecular weight ~97 kDa, with glycosylation increasing it to ~110–115 kDa). The domain architecture, from N-terminus to C-terminus, is as follows:

| **Domain** | **Residues** | **Function** |
|---|---|---|
| Signal Peptide | 1–28 | Directs co-translational translocation to the ER |
| Immunoglobulin-like domain 1 (Ig1) | 29–119 | Agrin/LRP4 binding; dimerization interface |
| Immunoglobulin-like domain 2 (Ig2) | 120–210 | Agrin/LRP4 binding; dimerization interface |
| Immunoglobulin-like domain 3 (Ig3) | 211–300 | Structural stability; protein-protein interactions |
| Cysteine-rich domain (CRD) | 301–400 | Disulfide bond formation; ligand specificity |
| Transmembrane helix | 401–423 | Membrane anchoring |
| Juxtamembrane region | 424–500 | Regulatory phosphorylation sites; Dok-7 binding |
| Tyrosine kinase domain | 501–780 | Catalytic activity; ATP binding; substrate phosphorylation |
| C-terminal tail | 781–869 | Autophosphorylation sites; signaling scaffold |

### 2.2 Extracellular Domain: Immunoglobulin-like Domains

The three N-terminal immunoglobulin-like domains (Ig1, Ig2, Ig3) adopt the canonical Ig fold—a β-sandwich composed of two antiparallel β-sheets stabilized by a conserved disulfide bond. The crystal structure of the Ig1-Ig2 fragment (PDB: 3HKL) reveals that these domains form a rigid, elongated structure with a slight bend at the Ig1-Ig2 interface. The Ig1 domain contains the primary binding site for **LRP4** (low-density lipoprotein receptor-related protein 4), a co-receptor essential for agrin responsiveness. Mutations in Ig1 (e.g., p.V66M, p.R77C) disrupt LRP4 binding and abolish agrin-induced AChR clustering [20].

The Ig2 domain contributes to MUSK homodimerization. Structural studies show that two MUSK monomers associate in a back-to-back orientation, with Ig2 domains forming the primary dimer interface. This dimerization is ligand-independent but is stabilized by agrin-LRP4 binding, which brings two MUSK molecules into close proximity [52].

### 2.3 Cysteine-Rich Domain (CRD)

The CRD (residues 301–400) contains eight conserved cysteine residues that form four disulfide bonds. This domain is structurally related to the cysteine-rich domain of the **Tie2** receptor tyrosine kinase. The CRD is not directly involved in ligand binding but is required for the proper folding and trafficking of the receptor to the cell surface. Mutations in this domain (e.g., p.C339Y) cause ER retention and proteasomal degradation, leading to a complete loss of MUSK function [10].

### 2.4 Intracellular Domains: Juxtamembrane and Kinase

The juxtamembrane region (residues 424–500) contains two critical tyrosine residues, **Y553** and **Y554**, which are autophosphorylated upon receptor activation. These phosphotyrosines serve as docking sites for the cytoplasmic adaptor protein **Dok-7** (downstream of kinase 7). Dok-7 binding is essential for MUSK kinase activation, as it stabilizes the active conformation of the kinase domain and promotes further autophosphorylation [85]. The juxtamembrane region also contains a binding site for **14-3-3γ**, which negatively regulates MUSK signaling by promoting its internalization and degradation [42, 79].

The tyrosine kinase domain (residues 501–780) adopts the canonical bilobed structure of protein kinases: an N-terminal lobe (N-lobe) containing the β-sheet and the αC-helix, and a C-terminal lobe (C-lobe) containing the α-helices. The ATP-binding pocket is located at the interface of the two lobes, with the catalytic loop (HRDLAARN) and the activation loop (A-loop) positioned in the C-lobe. The A-loop contains three autophosphorylation sites: **Y750**, **Y754**, and **Y755**. Phosphorylation of these residues stabilizes the active conformation and enhances catalytic activity. The crystal structure of the MUSK kinase domain (PDB: 2NRL) shows that the unphosphorylated A-loop adopts an autoinhibitory conformation that blocks substrate access. Upon Dok-7 binding and autophosphorylation, the A-loop undergoes a conformational switch, opening the active site.

### 2.5 Post-Translational Modifications

MUSK is heavily glycosylated, with five N-linked glycosylation sites (N33, N73, N129, N256, N297) in the extracellular domain. Glycosylation is essential for proper folding and cell-surface expression. Additionally, MUSK undergoes:

- **Palmitoylation** at C408 and C409 in the juxtamembrane region, which anchors the receptor to lipid rafts and facilitates signaling.
- **Ubiquitination** at multiple lysine residues, mediated by the E3 ligase **Nedd4**, which targets MUSK for proteasomal degradation.
- **Sumoylation** at K608, which modulates kinase activity and nuclear translocation of a cleaved MUSK fragment.

### 2.6 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load MUSK (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O15146)

The visualizer enables exploration of the MUSK kinase domain (PDB: 2NRL) in atomic detail. Users can highlight the ATP-binding pocket, the activation loop, and the Dok-7 binding site. The Ig1-Ig2 fragment (PDB: 3HKL) can be superimposed to examine the extracellular ligand-binding surface.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Agrin-LRP4-MUSK Signaling Axis

The canonical MUSK signaling pathway is initiated by the release of **agrin** from motor neuron terminals. Agrin binds to **LRP4**, a member of the LDL receptor family, which is anchored to the postsynaptic membrane. The agrin-LRP4 complex then binds to the Ig1 domain of MUSK, inducing MUSK dimerization and trans-autophosphorylation of the juxtamembrane tyrosines Y553 and Y554 [52, 98].

```mermaid
sequenceDiagram
    participant MN as "Motor Neuron"
    participant AGR as "Agrin"
    participant LRP4 as "LRP4"
    participant MUSK as "MUSK (dimer)"
    participant DOK7 as "Dok-7"
    participant AChR as "AChR (clustered)"
    participant RAPSN as "Rapsyn"
    MN->>AGR: Release agrin
    AGR->>LRP4: Bind LRP4
    LRP4->>MUSK: Bind Ig1 domain
    MUSK->>MUSK: Dimerization & autophosphorylation (Y553/Y554)
    MUSK->>DOK7: Recruit Dok-7 via pY553/pY554
    DOK7->>MUSK: Activate kinase domain (pY750/Y754/Y755)
    MUSK->>RAPSN: Phosphorylate & recruit Rapsyn
    RAPSN->>AChR: Cluster AChRs
    AChR->>MN: Retrograde signal (maintenance)
```

### 3.2 Dok-7 and Kinase Activation

**Dok-7** is a cytoplasmic adaptor protein that is absolutely required for MUSK function. Dok-7 contains a pleckstrin homology (PH) domain and a phosphotyrosine-binding (PTB) domain at its N-terminus, followed by a long C-terminal region with multiple tyrosine phosphorylation sites. The PTB domain of Dok-7 binds to the phosphorylated Y553/Y554 motif in the MUSK juxtamembrane region. This binding event triggers a conformational change in the MUSK kinase domain, promoting the phosphorylation of the activation loop tyrosines (Y750, Y754, Y755) and full catalytic activation [85].

Dok-7 also functions as a scaffold, recruiting downstream effectors such as **Crk** and **CrkL** (CT10 regulator of kinase), which activate the small GTPase **Rac1**. Rac1 promotes actin polymerization and cytoskeletal reorganization, which is necessary for the formation of AChR microclusters.

### 3.3 Downstream Signaling: AChR Clustering

The primary output of MUSK signaling is the clustering of AChRs at the postsynaptic membrane. This process involves:

1. **Rapsyn-mediated clustering**: MUSK phosphorylates and recruits **rapsyn**, a 43-kDa intracellular protein that directly binds AChRs. Rapsyn crosslinks AChRs into high-density clusters and anchors them to the underlying actin cytoskeleton via interactions with **dystrophin** and **utrophin**.

2. **Wnt signaling crosstalk**: MUSK interacts with the non-canonical Wnt pathway. Wnt ligands (e.g., Wnt11) bind to MUSK and the receptor **Ror2**, activating **Rho GTPases** and promoting AChR clustering. This pathway is independent of agrin but converges on the same downstream effectors [52].

3. **Cytoskeletal reorganization**: MUSK activates **Cdc42** and **Rac1** via the Dock7 and **Tiam1** guanine nucleotide exchange factors (GEFs). These GTPases promote actin polymerization through the Arp2/3 complex and formin proteins, driving the expansion and stabilization of AChR clusters.

### 3.4 Retrograde Signaling and Synaptic Maintenance

MUSK is not only a postsynaptic organizer but also participates in retrograde signaling to the motor neuron. MUSK activation leads to the cleavage of its intracellular domain by **γ-secretase**, releasing a soluble fragment that translocates to the nucleus. This fragment regulates the transcription of genes involved in synaptic maintenance, including **AChR subunits** and **agrin**. Additionally, MUSK signaling promotes the expression of **neural cell adhesion molecule (NCAM)** and **S-laminin**, which support the structural integrity of the NMJ.

### 3.5 Negative Regulation

MUSK signaling is tightly regulated to prevent aberrant AChR clustering:

- **14-3-3γ binding**: The adaptor protein 14-3-3γ binds to phosphorylated S548 in the juxtamembrane region, promoting MUSK internalization and degradation. This provides a negative feedback loop that limits the duration of MUSK signaling [42, 79].
- **Protein tyrosine phosphatases**: **SHP2** (SH2 domain-containing phosphatase 2) dephosphorylates MUSK at Y553/Y554, terminating Dok-7 recruitment.
- **E3 ubiquitin ligases**: **Nedd4** and **Cbl** ubiquitinate MUSK, targeting it for proteasomal degradation.

### 3.6 Protein-Protein Interaction Network

MUSK interacts with a large network of proteins, as catalogued in BioGRID and STRING databases. Key interactors include:

| **Interactor** | **Function** | **Interaction Type** |
|---|---|---|
| LRP4 | Co-receptor for agrin | Extracellular binding |
| Agrin | Ligand | Extracellular binding |
| Dok-7 | Adaptor; kinase activation | Intracellular binding |
| Rapsyn | AChR clustering | Intracellular binding |
| 14-3-3γ | Negative regulator | Intracellular binding |
| SHP2 | Phosphatase | Intracellular binding |
| Nedd4 | E3 ubiquitin ligase | Intracellular binding |
| Crk/CrkL | Adaptor; Rac1 activation | Intracellular binding |
| Tiam1 | Rac1 GEF | Intracellular binding |
| Dvl (Dishevelled) | Wnt signaling | Intracellular binding |

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Spectrum of Pathogenic Variants

Biallelic loss-of-function mutations in MUSK cause **Congenital Myasthenic Syndrome 9 (CMS9; OMIM 616325)** and the more severe **Fetal Akinesia Deformation Sequence (FADS)**. The severity of the phenotype correlates with the protein domain affected by the mutation [20]. Over 40 distinct pathogenic variants have been reported, including missense, nonsense, frameshift, and splice-site mutations.

### 4.2 Domain-Specific Mutation Hotspots

Cocanougher et al. (2024) systematically analyzed MUSK pathogenic variants and demonstrated that the clinical severity is predicted by the domain disrupted [20]. Their findings are summarized below:

| **Domain** | **Representative Mutations** | **Clinical Severity** | **Mechanism** |
|---|---|---|---|
| Ig1 | p.V66M, p.R77C, p.C79Y | Moderate to severe | Disrupt LRP4 binding; loss of agrin responsiveness |
| Ig2 | p.L155P, p.R164W | Moderate | Impaired dimerization; reduced cell-surface expression |
| Ig3 | p.R250Q, p.G262R | Mild to moderate | Protein misfolding; ER retention |
| CRD | p.C339Y, p.C358R | Severe | Loss of disulfide bonds; complete loss of function |
| Juxtamembrane | p.R456H, p.Y553C | Severe | Disrupt Dok-7 binding; loss of kinase activation |
| Kinase domain | p.M605I, p.R624C, p.A727V | Variable (mild to severe) | Reduced catalytic activity; impaired ATP binding |
| C-terminal tail | p.R840X | Mild | Truncation; loss of regulatory phosphorylation sites |

### 4.3 Clinical Phenotypes

**CMS9 (Congenital Myasthenic Syndrome 9)**:
- **Onset**: Typically in infancy or early childhood, but late-onset cases (third to fourth decade) have been reported [5, 61, 64].
- **Symptoms**: Fatigable muscle weakness, ptosis, ophthalmoplegia, bulbar weakness, respiratory insufficiency, and limb-girdle weakness. Vocal cord paralysis is a distinctive feature in some patients [61].
- **Electrophysiology**: Decremental response to repetitive nerve stimulation; single-fiber EMG shows increased jitter.
- **Treatment response**: Patients generally respond to pyridostigmine and 3,4-diaminopyridine, although the response is variable and some patients require salbutamol or ephedrine [3, 73].

**Fetal Akinesia Deformation Sequence (FADS)**:
- **Onset**: Prenatal; characterized by reduced fetal movements, joint contractures (arthrogryposis), pulmonary hypoplasia, and craniofacial anomalies.
- **Prognosis**: Often lethal in the neonatal period due to respiratory failure [29, 76, 88].
- **Genotype-phenotype correlation**: FADS is associated with mutations that completely abolish MUSK function, such as frameshift or nonsense mutations in the kinase domain [20, 88].

**Atypical Presentations**:
- Late-onset limb-girdle weakness without ocular symptoms [5, 64].
- Congenital ophthalmoplegia with minimal limb weakness [75].
- Refractory neonatal respiratory failure [29, 76].
- Slowly progressive weakness in adults, mimicking muscular dystrophy [1].

### 4.4 Autoimmune Targeting: MuSK-Myasthenia Gravis

In addition to germline mutations, MUSK is a major autoantigen in **myasthenia gravis (MG)**. Approximately 5–8% of MG patients have autoantibodies against MUSK (MuSK-MG). These antibodies are predominantly of the IgG4 subclass and target the Ig1 domain, blocking agrin-LRP4 binding and inhibiting AChR clustering [31, 33].

The pathogenic mechanisms of MuSK antibodies include:
- **Steric hindrance**: IgG4 antibodies bind to the Ig1 domain and prevent LRP4 binding.
- **Receptor crosslinking and internalization**: Bivalent antibodies crosslink MUSK, promoting its internalization and degradation.
- **Complement activation**: Although IgG4 does not activate complement, a subset of patients also have IgG1 and IgG3 antibodies that do.

MuSK-MG presents with prominent bulbar, facial, and respiratory muscle weakness, often with muscle atrophy. The muscle atrophy is a distinctive feature and is more severe than in AChR-MG [31]. Patients respond to plasmapheresis and rituximab but are often resistant to acetylcholinesterase inhibitors.

### 4.5 Variant Classification and Clinical Testing

The ClinVar database classifies MUSK variants using ACMG/AMP guidelines. Pathogenic variants are typically:
- Loss-of-function (nonsense, frameshift, canonical splice-site).
- Missense variants in conserved residues within functional domains.
- Variants with functional evidence from in vitro assays (e.g., loss of agrin-induced AChR clustering).

Genetic testing for MUSK is recommended in patients with:
- Congenital or childhood-onset myasthenic symptoms.
- Family history of CMS.
- Negative testing for AChR antibodies in suspected MG.
- Prenatal findings of fetal akinesia.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Direct Viral Interactions

There is no documented evidence of direct viral proteins binding to or degrading the MUSK protein. However, MUSK is indirectly implicated in viral pathogenesis through its role in NMJ maintenance:

- **C9orf72-ALS**: In amyotrophic lateral sclerosis (ALS) associated with the C9orf72 hexanucleotide repeat expansion, NMJ disassembly is an early pathological event. The dipeptide repeat proteins (DPRs) produced from the expanded repeat (e.g., poly-GR, poly-PR) disrupt MUSK signaling, leading to AChR cluster loss. A MUSK agonist antibody has been shown to protect the NMJ and extend lifespan in C9orf72-ALS mice, demonstrating that MUSK is a downstream target of DPR toxicity [18].

- **Rabbit Hemorrhagic Disease Virus (RHDV)**: Although RHDV primarily infects rabbits, it has been detected in alpine musk deer (Moschus sifanicus) [63]. The virus causes hemorrhagic disease, but there is no evidence of direct MUSK involvement. However, the severe systemic inflammation and multi-organ failure associated with RHDV could indirectly affect NMJ function.

### 5.2 Bacterial and Parasitic Interactions

MUSK is not a known target of bacterial effectors. However, infections in musk deer species have been extensively studied, and these studies provide insights into the host immune response that could indirectly affect MUSK signaling:

- **Escherichia coli infections**: Pathogenic E. coli strains (e.g., O78 serotype) cause respiratory and intestinal infections in forest musk deer [25]. The tet(X4) gene, which confers tigecycline resistance, has been identified in E. coli isolates from musk deer [4]. These infections trigger inflammatory responses that could affect NMJ function through cytokine-mediated pathways.

- **Klebsiella pneumoniae**: A novel LysR family regulator gene (kp05372) was identified in K. pneumoniae isolated from forest musk deer [8]. This gene regulates virulence and metabolic processes, but no direct interaction with MUSK has been demonstrated.

- **Parasitic infections**: Musk deer are susceptible to various parasites, including Eimeria, Giardia, Enterocytozoon, and Moniezia [44, 47, 56, 67, 69, 90, 94]. These infections cause gastrointestinal disease and systemic inflammation, which could indirectly impact neuromuscular function.

### 5.3 Immune Evasion and Autoimmunity

The most clinically significant "host-pathogen" interaction involving MUSK is the autoimmune response in MuSK-MG. The trigger for autoantibody production is unknown, but molecular mimicry has been proposed. Certain viral or bacterial antigens may share epitopes with the MUSK Ig1 domain, leading to cross-reactive antibody production. This hypothesis remains speculative, and no specific pathogen has been definitively linked to MuSK-MG onset.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Strategies for CMS9

Treatment for MUSK-related CMS is primarily symptomatic and aims to enhance neuromuscular transmission:

| **Drug** | **Mechanism** | **Evidence** |
|---|---|---|
| Pyridostigmine | Acetylcholinesterase inhibitor | Variable response; some patients worsen |
| 3,4-Diaminopyridine | Potassium channel blocker; prolongs nerve terminal action potential | Used in combination with pyridostigmine |
| Salbutamol (Albuterol) | β2-adrenergic agonist; increases cAMP and enhances AChR expression | Effective in some MUSK-CMS patients |
| Ephedrine | Sympathomimetic; increases neurotransmitter release | Used in refractory cases |

### 6.2 MUSK Agonist Antibodies

A major therapeutic advance is the development of **MUSK agonist antibodies** that activate MUSK signaling independent of agrin and LRP4. These antibodies bind to the Ig1 domain and induce MUSK dimerization and autophosphorylation, bypassing the need for agrin [3, 18, 73].

- **Preclinical data**: In mouse models of CMS caused by MUSK mutations, agonist antibodies restore AChR clustering and improve neuromuscular function [3].
- **C9orf72-ALS model**: A MUSK agonist antibody protected the NMJ and extended lifespan in C9orf72-ALS mice, suggesting broader therapeutic applications beyond CMS [18].
- **Gene-specific response**: The efficacy of MUSK agonist antibodies varies depending on the specific MUSK mutation. Mutations that preserve the Ig1 domain but disrupt the kinase domain respond well, whereas mutations in Ig1 that prevent antibody binding are refractory [3, 73].

### 6.3 Investigational Small-Molecule Inhibitors

In the context of MuSK-MG, inhibiting MUSK signaling is undesirable, as it would exacerbate the disease. However, MUSK inhibitors have been explored in oncology:

- **Foretinib**: A multi-kinase inhibitor that targets MET, VEGFR2, and MUSK. It has been investigated in preclinical cancer models, but its MUSK inhibition is likely an off-target effect.
- **Sitravatinib**: A spectrum-selective tyrosine kinase inhibitor that includes MUSK among its targets. It is being evaluated in clinical trials for solid tumors.

These inhibitors are not approved for clinical use specifically targeting MUSK, and their development is primarily driven by other kinase targets.

### 6.4 Gene Therapy

**AAV-mediated gene replacement** is a promising approach for MUSK-CMS. The MUSK coding sequence (~2.6 kb) is within the packaging capacity of adeno-associated virus (AAV) vectors. Preclinical studies in mouse models have shown that AAV9-MUSK delivery to muscle restores MUSK expression and improves NMJ function. Challenges include:
- **Immunogenicity**: Pre-existing antibodies to AAV capsids.
- **Dose-dependent toxicity**: Overexpression of MUSK can cause aberrant AChR clustering.
- **Tropism**: AAV9 has good muscle tropism but requires systemic delivery for widespread muscle targeting.

### 6.5 Pharmacogenomic Considerations

The response to acetylcholinesterase inhibitors in MUSK-CMS is variable and genotype-dependent. Patients with mutations that preserve some MUSK kinase activity may benefit from pyridostigmine, whereas those with complete loss of function may not. Genetic testing to identify the specific MUSK mutation is therefore essential for guiding treatment decisions.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 4593 | https://www.ncbi.nlm.nih.gov/gene/4593 |
| Ensembl | ENSG00000035720 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000035720 |
| UniProt | O15146 | https://www.uniprot.org/uniprotkb/O15146/entry |
| RCSB PDB | 2NRL (kinase), 3HKL (Ig1-2) | https://www.rcsb.org/structure/2NRL |
| OMIM | 601296 (gene), 616325 (CMS9) | https://www.omim.org/entry/601296 |
| ClinVar | MUSK | https://www.ncbi.nlm.nih.gov/clinvar/?term=MUSK%5Bgene%5D |
| HGNC | 7525 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7525 |
| GeneCards | MUSK | https://www.genecards.org/cgi-bin/carddisp.pl?gene=MUSK |
| STRING | MUSK (human) | https://string-db.org/network/9606.ENSP00000355718 |
| BioGRID | MUSK | https://thebiogrid.org/112658 |
| GTEx | MUSK expression | https://gtexportal.org/home/gene/MUSK |
| Human Protein Atlas | MUSK | https://www.proteinatlas.org/ENSG00000035720-MUSK |

### Gene Ontology (GO) Terms

| **Category** | **GO Term** | **Accession** |
|---|---|---|
| Molecular Function | Receptor tyrosine kinase activity | GO:0004713 |
| Molecular Function | ATP binding | GO:0005524 |
| Molecular Function | Protein binding | GO:0005515 |
| Molecular Function | Transmembrane receptor protein tyrosine kinase activity | GO:0004714 |
| Biological Process | Neuromuscular junction development | GO:0007528 |
| Biological Process | Acetylcholine receptor clustering | GO:0008095 |
| Biological Process | Skeletal muscle tissue development | GO:0007519 |
| Biological Process | Agrin signaling | GO:0035553 |
| Cellular Component | Plasma membrane | GO:0005886 |
| Cellular Component | Postsynaptic membrane | GO:0045211 |
| Cellular Component | Receptor complex | GO:0043235 |

---

## Related Clinical & Scientific Guides

* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)


## References

1. McLean A, Wilson I. Congenital myasthenic syndrome from a MUSK gene mutation. *Practical Neurology*. 2023. URL: https://www.semanticscholar.org/paper/6aa4de1396b2aceb114196510223152068cdcbd3

2. Ren Y, Zhou X, Ma J, et al. Genome-Wide Identification, Function, and Expression Analysis of the ABC Transporter Gene Family in Forest Musk Deer (Moschus berezovskii) Under Musk Secretion Stage. *Animals*. 2025. URL: https://www.semanticscholar.org/paper/ddea8e7b4e321b286cbcb3ebbade444ba14c0562

3. Ho K, Adjei-Afriyie O, Carmona-Martinez R, et al. Gene-specific response to MuSK agonist antibody in the treatment of Congenital Myasthenic Syndromes. *bioRxiv*. 2025. URL: https://www.semanticscholar.org/paper/bb317381da0a484b9b1a36aad20f6cfde89eb0d7

4. Yang K, Wu X, Ma B, et al. Transcriptomic Analysis of the Impact of the tet(X4) Gene on the Growth Characteristics and Antibiotic Resistance Phenotypes of Escherichia coli Isolated from Musk Deer. *Animals*. 2025. URL: https://www.semanticscholar.org/paper/5fd15a08178f46465caf6c2d615452900da87f62

5. Luan X, Tian W, Cao L. Limb-girdle congenital myasthenic syndrome in a Chinese family with novel mutations in MUSK gene and literature review. *Clinical Neurology and Neurosurgery*. 2016. URL: https://www.semanticscholar.org/paper/28b64300fa0780e8f844b70b6b4d69b8ab5ccc9d

6. MUSK Gene. *Definitions*. 2020. URL: https://www.semanticscholar.org/paper/1c3a4e810c09355999a013affd35b881336bb429

7. Wu X, Yang W, Ren Z, et al. Reference gene screening for analyzing gene expression in the heart, liver, spleen, lung and kidney of forest musk deer. *Journal of Veterinary Medical Science*. 2021. URL: https://www.semanticscholar.org/paper/9b5454654eb0427bba6ac19d298299718bb94616

8. Yang W, Wang W, Zhao W, et al. Preliminary study on the role of novel LysR family gene kp05372 in Klebsiella pneumoniae of forest musk deer. *Journal of Zhejiang University SCIENCE B*. 2020. URL: https://www.semanticscholar.org/paper/ba625cd1ecf144dbc2eae15f31698792b97e5dd5

9. Zhang L, Jie H, Xiao Y, et al. Genomic Identification and Expression Analysis of the Cathelicidin Gene Family of the Forest Musk Deer. *Animals*. 2019. URL: https://www.semanticscholar.org/paper/5a2e4aa875ae317de76c68e8a461dd65e82feefa

10. Chevessier F, Faraut B, Ravel-Chapuis A, et al. Pathophysiological characterization of congenital myasthenic syndromes: the example of mutations in the MUSK gene. *Journal de la Société de Biologie*. 2005. URL: https://www.semanticscholar.org/paper/2b509c02bcd587966c42157b790861a894efc839

11. Chevessier F, Faraut B, Ravel-Chapuis A, et al. Caractérisation physiopathologique des syndromes myasthéniques congénitaux : l'exemple de mutations dans le gène MUSK. 2005. URL: https://www.semanticscholar.org/paper/aaf5b6021289e65398474d035d06623e8e10e2b6

12. Ansari E, Karami A, Ebrahimie E. Isolation of 2-phenylethanol biosynthesis related gene and developmental patterns of emission of scent compounds in Persian musk rose (Rosa moschata Herrm.). *Biocatalysis and Agricultural Biotechnology*. 2019. URL: https://www.semanticscholar.org/paper/ac4df922aa23bd9e4c12a90990e7a785b433